BC Innovations | Jun 4, 2019
Distillery Therapeutics

PDE-1 inhibition could treat heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure Mouse studies suggest PDE-1 inhibitors could help treat a subtype of heart failure. In a mouse model of cardiac proteinopathy-induced heart failure with preserved ejection fraction, a tool compound...
BC Extra | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) said CEO Nessan Bermingham will resign, effective Jan. 1. EVP of R&D John Leonard will succeed Bermingham. Hematology and cancer company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said CEO Rajesh...
BC Week In Review | Feb 17, 2017
Financial News

Vermillion completes private placement

Diagnostic company Vermillion Inc. (NASDAQ:VRML) raised $5.6 million through the sale of 3.7 million shares at $1.40 and 2.8 million warrants at $0.13 in a private placement with company directors and management and existing investors...
BC Extra | Aug 1, 2016
Company News

Management tracks

Oncology company Array BioPharma Inc. (NASDAQ:ARRY) named Jason Haddock CFO. He was CFO at Berg LLC (Framingham, Mass.). Liquid biopsy company Inivata Ltd. (Cambridge, U.K.) named Timothy Shannon CFO. He was CFO at Baxano Surgical...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BC Week In Review | Sep 14, 2015
Company News

Vermillion sales and marketing update

Vermillion said it received a positive coverage decision for its OVA1 ovarian cancer test from CareFirst BlueCross BlueShield (BCBS). CareFirst BCBS covers about 3.4 million lives in Maryland, and the company said its coverage decision...
BC Week In Review | Jul 27, 2015
Financial News

Vermillion financial update

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date announced: 2015-07-17   Note: Vermillion raised $2.5 million through the sale of 1.3 million shares at $1.96 to cover the overallotment from its July 14...
BC Week In Review | Jul 20, 2015
Financial News

Vermillion completes follow-on

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date completed: 2015-07-14   Type: Follow-on   Raised: $16.4 million   Shares: 8.4 million   Price: $1.96   Shares after offering: 50.6 million   Underwriters: Canaccord;...
BC Extra | Apr 3, 2015
Company News

Management tracks

23andMe Inc. (Mountain View, Calif.) hired Robert Gentleman as VP of computational biology. Gentleman was senior director of bioinformatics and computational biology at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). At his new post...
BC Week In Review | Jan 5, 2015
Financial News

Vermillion completes private placement of common stock and warrants

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date completed: 2014-12-24   Type: Private placement of common stock and warrants   Raised: $10.5 million   Shares: 6.9 million   Price: $1.44   Shares after...
Items per page:
1 - 10 of 206
BC Innovations | Jun 4, 2019
Distillery Therapeutics

PDE-1 inhibition could treat heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure Mouse studies suggest PDE-1 inhibitors could help treat a subtype of heart failure. In a mouse model of cardiac proteinopathy-induced heart failure with preserved ejection fraction, a tool compound...
BC Extra | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) said CEO Nessan Bermingham will resign, effective Jan. 1. EVP of R&D John Leonard will succeed Bermingham. Hematology and cancer company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said CEO Rajesh...
BC Week In Review | Feb 17, 2017
Financial News

Vermillion completes private placement

Diagnostic company Vermillion Inc. (NASDAQ:VRML) raised $5.6 million through the sale of 3.7 million shares at $1.40 and 2.8 million warrants at $0.13 in a private placement with company directors and management and existing investors...
BC Extra | Aug 1, 2016
Company News

Management tracks

Oncology company Array BioPharma Inc. (NASDAQ:ARRY) named Jason Haddock CFO. He was CFO at Berg LLC (Framingham, Mass.). Liquid biopsy company Inivata Ltd. (Cambridge, U.K.) named Timothy Shannon CFO. He was CFO at Baxano Surgical...
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
BC Week In Review | Sep 14, 2015
Company News

Vermillion sales and marketing update

Vermillion said it received a positive coverage decision for its OVA1 ovarian cancer test from CareFirst BlueCross BlueShield (BCBS). CareFirst BCBS covers about 3.4 million lives in Maryland, and the company said its coverage decision...
BC Week In Review | Jul 27, 2015
Financial News

Vermillion financial update

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date announced: 2015-07-17   Note: Vermillion raised $2.5 million through the sale of 1.3 million shares at $1.96 to cover the overallotment from its July 14...
BC Week In Review | Jul 20, 2015
Financial News

Vermillion completes follow-on

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date completed: 2015-07-14   Type: Follow-on   Raised: $16.4 million   Shares: 8.4 million   Price: $1.96   Shares after offering: 50.6 million   Underwriters: Canaccord;...
BC Extra | Apr 3, 2015
Company News

Management tracks

23andMe Inc. (Mountain View, Calif.) hired Robert Gentleman as VP of computational biology. Gentleman was senior director of bioinformatics and computational biology at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). At his new post...
BC Week In Review | Jan 5, 2015
Financial News

Vermillion completes private placement of common stock and warrants

Vermillion Inc. (NASDAQ:VRML), Austin, Texas   Business: Diagnostic   Date completed: 2014-12-24   Type: Private placement of common stock and warrants   Raised: $10.5 million   Shares: 6.9 million   Price: $1.44   Shares after...
Items per page:
1 - 10 of 206